TriSalus Life Sciences (TLSI) Gross Margin (2022 - 2026)

TriSalus Life Sciences' Gross Margin history runs 5 years deep, the most recent figure standing at 86.18% for Q1 2026.

• On a quarterly basis, Gross Margin rose 249.0% year-over-year to 86.18% in Q1 2026; TTM through Mar 2026 was 85.07%, a 53.0% decrease from a year earlier, with the FY2025 full-year figure at 84.57%, down 148.0% from the prior year.
• Gross Margin eased to 86.18% in Q1 2026 per TLSI's latest filing, from 86.66% in the prior quarter.
• Across five years, Gross Margin topped out at 89.83% in Q4 2023 and bottomed at 74.71% in Q4 2022.
• The 5-year median for Gross Margin is 84.96% (2024), against an average of 84.3%.
• Across the five-year window, Gross Margin soared 1512 bps in 2023 and plunged 455 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 74.71% in 2022, then gained by 20 bps to 89.83% in 2023, then decreased by 5 bps to 85.28% in 2024, then increased by 2 bps to 86.66% in 2025, then declined by 1 bps to 86.18% in 2026.
• Per Business Quant, the three latest TLSI Gross Margin figures stand at 86.18% (Q1 2026), 86.66% (Q4 2025), and 83.52% (Q3 2025).